The White House has imposed a nationwide moratorium on Medicare enrollment for certain medical suppliers, including those providing prosthetics, wheelchairs, and mobility aids, sparking criticism from patients and advocacy groups.

Policy Details and Immediate Impact

The Centers for Medicare & Medicaid Services (CMS), under Administrator Dr. Mehmet Oz, announced the moratorium on February 26, 2026, citing a crackdown on ‘health care fraud.’

The policy targets Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) suppliers, effectively barring them from enrolling in Medicare for a period of time. This includes critical devices such as wheelchairs, walkers, prosthetic limbs, crutches, and canes, which are essential for the mobility and independence of millions of Americans.

According to the CMS announcement, the moratorium is intended to address ‘fraudulent practices and billing irregularities’ by suppliers. However, critics argue that the policy may inadvertently harm patients who rely on these devices for daily living.

Reaction from Advocacy Groups and Patients

The American Association of People with Disabilities (AAPD) and the National Council on Independent Living (NCIL) have condemned the policy, warning that it could leave vulnerable populations without access to essential medical equipment.

‘This policy is not about fighting fraud,’ said Sarah Thompson, a spokesperson for the AAPD. ‘It’s about making it harder for people with disabilities to get the support they need.’

Patients have also voiced concerns about the sudden implementation of the moratorium, with some stating that they were unaware of the policy until their devices were delayed or denied coverage.

John Carter, a veteran who uses a wheelchair due to combat-related injuries, said, ‘I didn’t know this was coming. Now I’m stuck waiting for a replacement chair, and I can’t work until I get it.’

What Analysts Say About the Policy

Health care analysts have raised questions about the timing and scope of the moratorium. According to a report by the Healthcare Policy Institute, the move could disrupt supply chains and increase wait times for critical medical devices, especially in rural areas where access to DMEPOS suppliers is already limited.

Dr. Emily Chen, a health policy expert at the University of California, said, ‘This is a poorly targeted policy that risks harming patients more than it will deter fraud. There are more effective ways to address billing irregularities without cutting off access to essential care.’

The CMS has not provided specific details on how long the moratorium will last or what criteria will be used to determine which suppliers are eligible to reapply for Medicare enrollment. This lack of clarity has further fueled concerns among providers and patients alike.

Meanwhile, advocacy groups are preparing to challenge the policy in court, arguing that it violates the Americans with Disabilities Act (ADA) and the Medicare Access and CHIP Reauthorization Act (MACRA). A federal lawsuit is expected to be filed within the next two weeks.

As the policy takes effect, the White House faces mounting pressure to reconsider its approach. The CMS has not yet responded to requests for comment on the potential impact of the moratorium on patients and suppliers.